TABLE 1

Detection of Abi, D4A, and 5α-Abi and their glucuronide derivatives in five prostate cancer patients under AA treatment

Patients	Steady State Blood Levels^{^a}
	Abi		D4A		5α-Abi		Abi-G1		Abi-G2		D4A-G		5α-Abi-G
	ng/ml	nM	ng/ml	nM	ng/ml	nM	ng/ml	nM	ng/ml	nM	ng/ml	nM	ng/ml	nM
AA-009	6.71	19.23	0.33	0.95	1.07	3.07	0.41	0.78	0.26	0.49	0.04	0.08	0.06	0.11
AA-015	35.10	100.57	1.92	5.53	10.00	28.65	0.81	1.54	1.39	2.64	0.18	0.34	0.60	1.14
AA-024	15.90	45.56	1.11	3.20	6.29	18.02	0.47	0.89	0.94	1.79	0.10	0.19	0.46	0.87
AA-025	62.60	179.37	3.53	10.17	8.88	25.44	0.34	0.65	1.28	2.43	0.02	0.04	0.20	0.38
AA-026	58.80	168.48	4.93	14.21	4.66	13.35	1.12	2.13	1.23	2.34	0.10	0.19	0.37	0.70
Mean	35.82	102.64	2.36	6.81	6.18	17.71	0.63	1.20	1.02	1.94	0.09	0.17	0.34	0.64
S.D.	24.95	71.49	1.86	5.36	3.55	10.16	0.33	0.62	0.46	0.87	0.06	0.12	0.21	0.40
CV	70%		79%		57%		52%		45%		69%		62%

↵^a Plasmatic concentrations correspond to C_min values and are similar to those observed in a previous group of five patients recruited at the same hospital (Caron et al., 2019).